Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (Jinnah Hospital)
- Development stage
- Unknown
- Lead developer
- Jinnah Burn and Reconstructive Surgery Centre
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord-derived mesenchymal stem cells (UCMSCs) developed by Jinnah Hospital represent an investigational cell-based biologic therapy for the treatment of moderate to severe COVID-19. These cells are isolated from human umbilical cord tissue collected from healthy pregnancies and expanded for therapeutic use. The primary mechanism of action involves potent immunomodulatory effects and paracrine signaling, which aim to suppress the hyperinflammatory "cytokine storm" and systemic inflammation associated with severe SARS-CoV-2 infection. By modulating the host immune response and promoting tissue regeneration, UCMSCs are intended to prevent acute respiratory distress syndrome (ARDS), septic shock, and multi-organ failure. The safety and efficacy of this therapy are being evaluated through intravenous infusions in clinical trials led by a consortium at Jinnah Hospital, Lahore.
- Other names
- UCMSCsJinnah Hospital UCMSCsumbilical cord-derived mesenchymal stem cells-Jinnah Hospital-COVID-19
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (Jinnah Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Jinnah Hospital).